Premium
Influence of the matrix metalloproteinase inhibitor batimastat (BB‐94) on periodontal bone destruction in Sprague‐Dawley rats
Author(s) -
Björnsson Magnús Jón,
HavemosePoulsen Anne,
Stoltze Kaj,
Holmstrup Palle
Publication year - 2004
Publication title -
journal of periodontal research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.31
H-Index - 83
eISSN - 1600-0765
pISSN - 0022-3484
DOI - 10.1111/j.1600-0765.2004.00740.x
Subject(s) - medicine , matrix metalloproteinase , periodontal disease , dentistry , pathology
Background: Matrix metalloproteinases (MMPs) are proteolytic enzymes capable of degrading most macromolecules of the extracellular matrix. It has been assumed that an association exists between MMP activity and periodontal disease progression, but the precise role of MMPs in disease progression is still not fully clarified. Batimastat, or BB‐94, is a synthetic broad‐spectrum MMP inhibitor not previously examined in periodontal research. If there is an association between MMP activity and periodontal disease progression, then batimastat might be expected to reduce the progression of experimental periodontal disease in rats. Objectives: The objective of the present study was to determine the effects of batimastat on periodontal status in healthy Sprague‐Dawley (SPRD) rats as well as in rats with ligature‐induced experimental periodontal disease. Methods and Results: Periodontal bone destruction was used as a means of evaluating periodontal destruction by measuring periodontal bone loss on defleshed rat jaws and periodontal bone support on radiographs of the jaws. There was significantly more periodontal bone destruction in the groups treated with batimastat than in the placebo and control groups. This accounted for both ligated and non‐ligated groups, irrespective of whether periodontal bone loss ( p < 0.05) or periodontal bone support ( p < 0.05) were measured. Conclusion: In conclusion, the results of this study did not support the hypothesis that the MMP inhibitor batimastat could reduce the progression of experimental periodontal disease in rats. Instead, significantly increased bone destruction was found in rats treated with batimastat.